SCHEMBL13304928

SCHEMBL13304928

Cc1cnn2c(NCc3ccc4[nH]cnc4c3)cc(C3CCNCC3)nc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 4/20 0.51
▸ CHEK1 O14757 6/20 0.41
▸ CDK2 P24941 5/20 0.41
▸ CCNA2 P20248 1/20 0.41
▸ CCNA1 P78396 1/20 0.41
▸ CDK1 P06493 4/20 0.39
▸ CDK7 P50613 4/20 0.39
▸ CCNE1 P24864 3/20 0.39
▸ CCNH P51946 3/20 0.39
▸ MNAT1 P51948 3/20 0.39
▸ PDE10A Q9Y233 1/20 0.36
▸ CDK9 P50750 3/20 0.34
▸ CDK5 Q00535 3/20 0.34
▸ CDK4 P11802 2/20 0.34
▸ CDK6 Q00534 2/20 0.34
▸ CDK8 P49336 1/20 0.34
▸ GPR39 O43194 1/20 0.34
▸ BCDIN3D Q7Z5W3 1/20 0.34
▸ MEN1 O00255 1/20 0.33
▸ NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12952905 0.90 GSK3B (0.65) GSK3BCHEK1CDK2CCNA2CCNA1
SCHEMBL13146206 0.90 GSK3B (0.51) GSK3BCHEK1CDK2CCNA2CCNA1
SCHEMBL12953011 0.81 GSK3B (0.63) GSK3BCHEK1CDK2CCNA2CCNA1
SCHEMBL13304684 0.81 GSK3B (0.49) GSK3BCHEK1CDK2CCNA2CCNA1
SCHEMBL14412770 0.80 GSK3B (0.67) GSK3BCHEK1CDK2CCNA2CCNA1
SCHEMBL13304607 0.79 GSK3B (0.79) GSK3BCHEK1CDK2CCNA2CCNA1
SCHEMBL13305377 0.77 CDK2 (0.53) GSK3BCDK2CCNA2CCNA1GPR39
SCHEMBL11930866 0.74 GSK3B (0.63) GSK3BCHEK1CDK2CCNA2CCNA1
SCHEMBL13305591 0.73 GSK3B (0.52) GSK3BCHEK1CDK2CCNA2CCNA1
SCHEMBL13305605 0.72 GSK3B (0.55) GSK3BCHEK1CDK2CCNA2CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537116-B1 PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES SCHERING CORP (US) 2010-06-02 — — EP disclosed
Send feedback